a-1155463 has been researched along with Leukemia--Myeloid--Acute* in 1 studies
1 other study(ies) available for a-1155463 and Leukemia--Myeloid--Acute
| Article | Year |
|---|---|
MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
Aberrant over-expression of BCL-2 family proteins (BCL-2, BCL-xL, MCL-1) are associated with hematological malignancies. Antagonists of BCL-2 family proteins include BCL-2-selective inhibitor ABT-199, MCL-1-selective inhibitor A-1210477, BCL-xL-selective inhibitor A-1155463. In this study, we evaluated their potential inhibitory effectiveness. Our data showed that OCI-AML3 cells and U937 cells were resistant to BCL-2-selective inhibitor ABT-199 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Benzothiazoles; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Isoquinolines; Leukemia, Myeloid, Acute; Mice; Mice, Transgenic; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; U937 Cells; Xenograft Model Antitumor Assays | 2019 |